Metaphore Pharmaceuticals, Inc.

St. Louis, MO 63114

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $1.16MM
First Award Date 08/10/96
Most Recent Award Date 09/30/01

Key Personnel

Last Name Name Awards Contact
Richon Victoria M. Richon 2
Slomczynska Urszula Slomczynska 5
Salvemini Daniela Salvemini 3

10 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/01 - 03/29/03

DESCRIPTION (provided by applicant): Recent studies in models of cardiac ischemia/reperfusion injury have shown that a significant reduction in tissue damage from infarction can be achieved using MetaPhor's proprietary superoxide dismutase mimetics (SODm). In preliminary studies we found that M40403 a selecti...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/06/01 - 07/31/03

DESCRIPTION (provided by applicant): The lymphokine interleukin 2 (IL-2) is currently approved by the FDA as therapy for metastatic renal cell carcinoma and malignant melanoma. The clinical use of IL-2 has been limited by its severe side effects, particularly hypotension. Because of such dose-limiting side effects...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/00 - 08/31/02

Our objective in this Phase II study is to discover a number of novel iron chelators which are suitable candidates for development as an orally available drug. These candidates will be further evaluated in Phase III for filing of an IND and subsequent clinical studies. In Phase I, we established the feasibility of using solid phase combinatorial...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/10/00 - 08/31/01

Recent studies in several models of pain have shown that significant reduction in the pain response can be achieved using MetaPhore's proprietary SuperOxide Dismutase mimetics. One of these, M40403, a highly active and selective SOD catalyst possessing 'in vivo' stability, is highly effective in attenuating the pain response. Baked on our observ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/99 - 08/31/00

Our objective in this Phase II study is to discover a number of novel iron chelators which are suitable candidates for development as an orally available drug. These candidates will be further evaluated in Phase III for filing of an IND and subsequent clinical studies. In Phase I, we established the feasibility of using solid phase combinatorial...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/15/99 - 08/14/00

DESCRIPTION (Adapted from the application): This proposal aims to establish the feasibility of exploiting metal-siderophore transport systems in Mycobacterium tuberculosis as a route for the development of a new class of antibiotics. Mycobactins, exochelins, and other siderophores function to sequester essential metals,...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/25/98 - 11/30/98

DESCRIPTION (Adapted from the application): The focus of this proposal is development of solid phase technology for the synthesis of combinatorial libraries of siderophore analogs. Some members of this class of compounds, such as deferoxamine, have been shown to be effective in diseases t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/15/98 - 01/14/99

DESCRIPTION (Adapted from the application): The applicants propose to exploit the metal-siderophore transport systems in bacteria to develop a new class of antibiotics. In particular, aerobactin and other siderophores have been shown to sequester essential metals, such as iron in bacteria. This proc...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/97 - 08/31/97

The focus of this proposal is development of solid phase technology for the synthesis of combinatorial libraries of bicyclams. Some members of this class have been showed to be very potent inhibitors of HIV (human immunodeficiency virus) multiplication with very low cellular toxicity. By lead optimization, c...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/10/96 - 02/09/97

Load More